Abstract Dysregulation of cyclin-dependent kinase 4/6 (CDK4/6) occurs in cancer and is targeted by CDK4/6 inhibitors (CDK4/6i) including palbociclib (PD). CDK4/6i triggers quiescence (reversible) which transitions to senescence (irreversible) following prolonged exposure. Resolving the program that directs this transition is critical to overcoming CDK4/6i resistance and improving the efficacy of CDK4/6 inhibitors.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ata
Contact Ata, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack